JP2021528496A5 - - Google Patents

Info

Publication number
JP2021528496A5
JP2021528496A5 JP2021520477A JP2021520477A JP2021528496A5 JP 2021528496 A5 JP2021528496 A5 JP 2021528496A5 JP 2021520477 A JP2021520477 A JP 2021520477A JP 2021520477 A JP2021520477 A JP 2021520477A JP 2021528496 A5 JP2021528496 A5 JP 2021528496A5
Authority
JP
Japan
Prior art keywords
cancer
pnd
pharmaceutically acceptable
acceptable salt
tumor
Prior art date
Application number
JP2021520477A
Other languages
English (en)
Japanese (ja)
Other versions
JP7510411B2 (ja
JP2021528496A (ja
JPWO2019244050A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/055130 external-priority patent/WO2019244050A1/en
Publication of JP2021528496A publication Critical patent/JP2021528496A/ja
Publication of JP2021528496A5 publication Critical patent/JP2021528496A5/ja
Publication of JPWO2019244050A5 publication Critical patent/JPWO2019244050A5/ja
Application granted granted Critical
Publication of JP7510411B2 publication Critical patent/JP7510411B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021520477A 2018-06-19 2019-06-19 癌療法のための二機能性組成物 Active JP7510411B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2018902181 2018-06-19
AU2018902181A AU2018902181A0 (en) 2018-06-19 Bifunctional compositions for the treatment of cancer
PCT/IB2019/055130 WO2019244050A1 (en) 2018-06-19 2019-06-19 Bifunctional compositions for the treatment of cancer

Publications (4)

Publication Number Publication Date
JP2021528496A JP2021528496A (ja) 2021-10-21
JP2021528496A5 true JP2021528496A5 (https=) 2022-04-26
JPWO2019244050A5 JPWO2019244050A5 (https=) 2022-04-26
JP7510411B2 JP7510411B2 (ja) 2024-07-03

Family

ID=68983509

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021520477A Active JP7510411B2 (ja) 2018-06-19 2019-06-19 癌療法のための二機能性組成物

Country Status (16)

Country Link
US (2) US12201626B2 (https=)
EP (1) EP3793544B1 (https=)
JP (1) JP7510411B2 (https=)
CN (1) CN112672741A (https=)
AU (1) AU2019291491B2 (https=)
BR (1) BR112020025946A2 (https=)
CA (1) CA3102051A1 (https=)
CL (1) CL2020003306A1 (https=)
GB (1) GB2587172B (https=)
IL (1) IL279609B2 (https=)
MX (1) MX2020014096A (https=)
MY (1) MY206540A (https=)
PH (1) PH12020552171A1 (https=)
RU (1) RU2764175C1 (https=)
SG (1) SG11202011503YA (https=)
WO (1) WO2019244050A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220306603A1 (en) * 2019-06-12 2022-09-29 The Governors Of The University Of Alberta Targeting dna repair in tumor cells via inhibition of ercc1-xpf
KR20220140515A (ko) 2020-01-13 2022-10-18 버지 애널리틱스, 인크. 치환된 피라졸로-피리미딘 및 그의 용도
CN115317625B (zh) * 2021-12-24 2023-08-08 南通大学附属医院 一种小干扰rna在制备改善鼻咽癌预后的药物中的应用
CN114511462B (zh) * 2022-02-11 2023-04-18 电子科技大学 一种视觉图像增强方法
WO2025251699A1 (zh) * 2024-06-07 2025-12-11 北京三博脑科医院有限公司 一种硝唑尼特及其药学上可接受的盐在制备抗造釉细胞型颅咽管瘤药物中的应用
CN119064582B (zh) * 2024-09-02 2025-05-27 南方医科大学南方医院 RIPK1 O-GlcNAc糖基化抑制剂在制备增强肾细胞癌舒尼替尼敏感性药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1135977C (zh) * 1999-07-19 2004-01-28 中国医学科学院中国协和医科大学血液学研究所血液病医院 咯萘啶在制备抗肿瘤药物和逆转肿瘤多药耐药性的药物中的应用
KR100390332B1 (ko) * 2000-08-02 2003-07-07 유원민 항말라리아제와 항암제의 병용투여에 의한 항암제 복합 조성물
US20120172292A1 (en) * 2009-09-10 2012-07-05 New York University Method for protection of antimicrobial and anticancer drugs from inactivation by nitric oxide
US9439878B2 (en) * 2010-06-03 2016-09-13 Douglas Tyler McKenzie Use of lumefantrine and related compounds in the treatment of cancer
CN103570711B (zh) * 2012-07-24 2016-08-03 中国科学院上海药物研究所 一种咯萘啶类化合物及其用途
US10512641B2 (en) * 2015-06-01 2019-12-24 University Of Kentucky Research Foundation Chloroquine induction par-4 and treatment of cancer
US20200215074A1 (en) * 2017-06-22 2020-07-09 Cipla Limited Method of Treatment of Cancer

Similar Documents

Publication Publication Date Title
JP2021528496A5 (https=)
US12150942B2 (en) Cerdulatinib for treating myeloma
GB2587172A (en) Bifunctional compositions for the treatment of cancer
RU2019126562A (ru) ЛЕЧЕНИЕ ТРИЖДЫ НЕГАТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, ХАРАКТЕРИЗУЮЩЕГОСЯ ЭКСПРЕССИЕЙ Trop-2, С ПОМОЩЬЮ САЦИТУЗУМАБА ГОВИТЕКАНА И ИНГИБИТОРА Rad51
JP2022537384A (ja) ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン
RU2020114632A (ru) Терапевтические способы, относящиеся к ингибиторам hsp90
US9119877B2 (en) Therapeutic combination comprising a Cdc7 inhibitor and an anti-neoplastic agent
CN110536702A (zh) 使用hsp90抑制剂治疗癌症的方法
JP2020515600A (ja) 抗がん併用療法
CA2806614A1 (en) Combinatory cancer treatment
RU2010151602A (ru) Комбинированная терапия с помощью рм00104 и другого противоопухолевого средства
CN112043702A (zh) 用于联合治疗结直肠癌的喹啉类化合物
WO2023035223A1 (zh) 药物组合物及其用途
JP2016515619A5 (https=)
EP4252774A1 (en) Combination therapy for treating pik3ca-mutated cancer
KR102936318B1 (ko) 소세포폐암의 병용 치료용 퀴놀린 유도체
CN114469949A (zh) 用于治疗弥漫大b细胞淋巴瘤的喹啉衍生物
JPWO2023025307A5 (https=)
CN112121048A (zh) 用于联合治疗食管癌的喹啉类化合物
JPWO2019244050A5 (https=)
CN113750096A (zh) 用于治疗外周t细胞淋巴瘤的喹啉衍生物
WO2017184534A1 (en) Methods and compositions for improving safety and efficacy of natural killer cell immunotherapy
RU2025135585A (ru) Кристаллическая форма ингибитора enpp1
CA3231639A1 (en) Triple-agent therapy for cancer treatment
RU2023105427A (ru) АНТИ-CD79b АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ